Alcohol withdrawal delirium

Summary

Alcohol withdrawal delirium (MONDO:0006642) is a disease and 6 clinical trials. Top therapeutic interventions include dexmedetomidine, lorazepam, and phenobarbital. A subtype of alcohol-induced mental disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	alcohol withdrawal delirium
Mondo ID	MONDO:0006642
EFO	EFO:1000800
MeSH	D000430
SNOMED CT	8635005
UMLS	C0001957
MedGen	1398
MedDRA	10001610
Is cancer (heuristic)	no

Also known as: alcohol withdrawal associated autonomic hyperactivity · alcohol withdrawal hallucinosis · alcohol withdrawal induced delirium Tremens · alcohol withdrawal-induced delirium Tremens · autonomic hyperactivity, alcohol withdrawal associated · delirium Tremens · delirium Tremens, alcohol withdrawal induced · delirium, alcohol withdrawal · hallucinosis, alcohol withdrawal

Disease family

This is a subtype of alcohol-induced mental disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › alcohol-induced mental disorder › alcohol withdrawal delirium

Related subtypes (2): fetal alcohol spectrum disorder, alcoholic psychosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01362205	PHASE4	TERMINATED	Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
NCT03877120	PHASE4	COMPLETED	Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O’horán
NCT04156464	PHASE4	UNKNOWN	Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
NCT00597701	Not specified	COMPLETED	Treating Alcohol Withdrawal With Oral Baclofen
NCT03470168	Not specified	COMPLETED	Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome
NCT03586089	Not specified	TERMINATED	Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXMEDETOMIDINE	4	4
LORAZEPAM	4	2
PHENOBARBITAL	4	2
BACLOFEN	4	1
MEDETOMIDINE	3	1